Big win for Astellas ($ALPMY ) and Pfizer ( $PFE (+0,57%) )!

China’s NMPA just approved Padcev™ (enfortumab vedotin) + Keytruda® as the first non-platinum option in 40 years for locally advanced/metastatic urothelial cancer (la/mUC).

🔑 Key Stats from Phase 3 EV-302 Trial:

Overall Survival: 31.5 months (vs. 16.1 with chemo) 🚀

Progression-Free Survival: 12.5 months (vs. 6.3 with chemo) 📉

With over 92K bladder cancer cases in China last year, this approval disrupts decades of reliance on platinum-based chemo and opens a massive market opportunity.

This approval underscores a pivotal shift in treatment options for bladder cancer, providing new opportunities for patients and adding momentum to Astellas and Pfizer’s oncology portfolios.